1 the sclera subjects to vigorous clearance by
episcleral and choroidal circulation; in addition, the p
2 P) was elevated by laser photocoagulation of
episcleral and limbal veins.
3 oma treated with iodine 125 or ruthenium 106
episcleral brachytherapy between January 1, 2004, and De
4 A total of 375 eyes treated with
episcleral brachytherapy for posterior uveal melanoma fr
5 Vision loss following
episcleral brachytherapy for uveal melanoma is difficult
6 melanoma from 1995 to 2016 and treated with
episcleral brachytherapy were included.
7 ing brachytherapy are uncommon 5 years after
episcleral brachytherapy.
8 counseling for patients being evaluated for
episcleral brachytherapy.
9 s developed to predict vision loss following
episcleral brachytherapy.
10 t were secured by suturing, to form a sealed
episcleral chamber that was filled with a fluorescein so
11 These results suggest that the
episcleral circulation is under tonic neural control and
12 The
episcleral cyclosporine implant shows promise in reducin
13 This preclinical evaluation showed that the
episcleral cyclosporine implant was safe, delivered pote
14 Episcleral cyclosporine implants were manufactured with
15 An
episcleral exoplant facilitates diffusion of fluorescein
16 dium fluorescein (fluorescein, 376 Da) or an
episcleral exoplant loaded with fluorescein.
17 More than 34% of the
episcleral hydrogel explants developed symptomatic swell
18 The ability of an
episcleral implant at the equator of the eye to deliver
19 assess the toxicity of a cyclosporine (CsA)
episcleral implant for the prevention of high-risk kerat
20 ysis of the ocular drug distribution from an
episcleral implant showed that the elimination rate cons
21 porine in the subconjunctival space with the
episcleral implant was an effective means of delivering
22 Episcleral implants are safe and effective at delivering
23 In vivo,
episcleral implants at the equator of the eye did not de
24 Episcleral implants in vivo delivered a mean total of 2.
25 CsA
episcleral implants were made with a high (implant A) or
26 patients with unilateral anterior scleral or
episcleral inflammation.
27 leading to optic nerve damage was induced by
episcleral injection of hypertonic saline, which caused
28 racterized by corneal haze, conjunctival and
episcleral injection, corneal infiltrates, and neovascul
29 The three-vein
episcleral/
limbal vein occlusion model for inducing glau
30 male Wistar rats (150-180 g) by cautery of 3
episcleral/
limbal veins.
31 t surgical removal of a symptomatic, swollen
episcleral MIRAgel (MIRA Inc., Waltham, MA) explant at t
32 with equine recurrent uveitis (ERU) received
episcleral or deep scleral lamellar CsA implants and wer
33 There was no case of
episcleral or orbital retinoblastoma extension or remote
34 ye retention in patients treated with repeat
episcleral plaque brachytherapy (EPBT) for locally recur
35 ; meibomian glands; skin; retina-choroid; or
episcleral regions.
36 mors were commonly dome shaped (75%) with an
episcleral sentinel vessel (75%).
37 t barriers to the movement of drugs from the
episcleral space into the vitreous in vivo.
38 Diffusion of CsA across the sclera from the
episcleral space was not a feasible method of drug deliv
39 depot of drug (100 microl) was added to the
episcleral surface while perfusing an irrigating solutio
40 vivo studies before subtenon TA injection or
episcleral TA-film implantation.
41 y conjunctivae bilaterally, having undergone
episcleral tattooing 7 weeks previously.
42 the few people in Britain to have undergone
episcleral tattooing for cosmetic purposes.
43 Episcleral tattooing is carried out by individuals with
44 ribing the first forays into the practice of
episcleral tattooing.
45 . 4%) or ciliary body (30% vs. 8%) lymphoma,
episcleral vascular congestion (40% vs. 16%), anterior c
46 hours) was a near complete blanching of the
episcleral vasculature, and a poorly defined wave was mi
47 o provide a more reliable approach to assess
episcleral vasculature.
48 by injection of hypertonic saline solution,
episcleral vein cauterization, or optic nerve transectio
49 Hypertonic saline was injected into a single
episcleral vein in 17 animals and awake IOP measured in
50 duced by hypertonic saline injection into an
episcleral vein in 20 adult male Brown-Norway rats.
51 cular pressure (IOP) was produced in rats by
episcleral vein injection of hypertonic saline (N = 30).
52 Episcleral vein injection of hypertonic saline is more l
53 own Norway rats (N = 16) received unilateral
episcleral vein injection of hypertonic saline to elevat
54 A single
episcleral vein injection of hypertonic saline was used
55 ateral IOP elevation was produced in rats by
episcleral vein injection of hypertonic saline.
56 monitor chronically elevated IOP produced by
episcleral vein injection of hypertonic saline.
57 own Norway rats were-administered unilateral
episcleral vein injections of hypertonic saline to produ
58 induced in the left eye by hypertonic saline
episcleral vein injections.
59 to optic nerve damage was induced using the
episcleral vein occlusion model.
60 elevated by injecting 1.9 M saline into the
episcleral vein, as previously described in Brown Norway
61 532 nm aimed at the trabecular meshwork and
episcleral veins (combination treatment group) or only a
62 mice by laser photocoagulation of limbal and
episcleral veins 270 degrees to 300 degrees circumferent
63 DTPA from the subconjunctival space into the
episcleral veins and conjunctival lymphatics was 3-log u
64 Diode laser treatment of ICG saturated
episcleral veins causes a chronic elevation of IOP and s
65 ser cauterization of trabecular meshwork and
episcleral veins in rat eyes.
66 Laser photocoagulation of limbal and
episcleral veins induces transient ocular hypertension i
67 sive eye in which cauterizing limbal derived
episcleral veins leads to increase in the intraocular pr
68 flow pathway, preventing flow to the visible
episcleral veins.
69 in rats by hypertonic saline injections into
episcleral veins.
70 d by injection of hypertonic saline into the
episcleral veins.
71 s with 2- to 3-microm tips used to cannulate
episcleral veins.
72 mice by laser photocoagulation of limbal and
episcleral veins.
73 in rats by hypertonic saline injections into
episcleral veins.
74 e (12.5-14.5 mmHg) by cauterization of three
episcleral veins.
75 rapid, non-invasive delineation of abnormal
episcleral venous plexus secondary to dural CCF.
76 Episcleral venous pressure (EVP) was measured by gradual
77 Measurements of IOP,
episcleral venous pressure (EVP), conventional outflow f
78 of the variation in IOP is due to changes in
episcleral venous pressure (EVP).
79 etermined by multiple flow-rate infusion and
episcleral venous pressure (Pe) measured by manometry.
80 d be reconciled only if nocturnal changes in
episcleral venous pressure and/or uveoscleral flow occur
81 Current measurements of
episcleral venous pressure are either invasive or provid
82 mechanisms are exertion-related increase in
episcleral venous pressure or ocular compression from sl
83 stigate whether changes in outflow facility,
episcleral venous pressure, or uveoscleral flow at night
84 ique altered tonographic outflow facility or
episcleral venous pressure.
85 After total outflow was measured, the
episcleral vessels were blocked with cyanoacrylate to el
86 IOP was produced in rats by cautery of three
episcleral vessels.